Clene Inc., a biopharmaceutical company focused on neurodegenerative diseases, announced a $7 million underwritten offering of 1 million common shares at $7 each to a single investor. The funds will support general corporate expenses and advance the development of their lead drug candidate CNM-Au8®, including NDA preparation, ongoing and future clinical trials, manufacturing expansion, and early-stage research. The offering is expected to close around May 6, 2026. This capital raise is crucial for Clene's efforts to bring new treatments for diseases like ALS and multiple sclerosis to market.
Crédit Agricole S.A. disclosed its voting rights status as of June 30, 2026, reporting a total of 3,025,902,350 shares and an almost equal number of theoretical voting rights. The exercisable voting rights, accounting for shares held in treasury and ...
The Sweden flu diagnostic and treatment market is projected to grow from USD 172.1 million in 2026 to USD 210.3 million by 2031, at a 4.1% CAGR. Growth is driven by high influenza burden among seniors, increased demand for rapid molecular diagnostics...
In Q2 2026, NIU Technologies sold 434,687 electric mobility units, marking a 25% year-over-year increase in China with 402,202 units sold. Growth was fueled by strong demand for core and new smart electric models, including the NX 2026 long-range mot...
HSBC Continental Europe announced that no stabilisation activities were performed in relation to the EUR 750 million bond offering by Assicurazioni Generali S.p.A., which carries a 4.406% coupon due June 2037. This means the stabilisation manager did...
RENK Group AG, through its subsidiary RENK GmbH, has signed a binding agreement to acquire David Brown Defence, a UK company specializing in high-precision gearboxes for naval and land defense. This acquisition will strengthen RENK's naval sector por...
